{"ticker": {"uuid": "a4be6d92-74d2-4e2b-8ac1-44a6d7909153", "symbol": "TTRX", "name": "Turn Therapeutics Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Turn Therapeutics Ord Shs (TTRX) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5wVFNad2lYYXhSOEhDSm1KQkhaQ2p4VUh0T0JlVHZnejJqdmtVSzcyM2x2c1ZhSlhQa1ZITS1TajVGdVpGY0xVamRPbEREd1NmbkRIZGZoenBDYWFjOEJvU2VSZUhjRXROazVEOV9QOGY?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:40:16+00:00", "published_display": "22 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Valuation: PE, PB & Fair Value Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9BUFEwR1BVSlJXbVQ2bFV0VkxEOFZxcTZCSDB6YzNpV1ZlOTBMRmQ1S3dEc082OEZua0dvc0pnczBJMFpUOW11ZmNfcmt4NzdnRzdDV2ZiMkt2OGQtOS1uZWdlNjNMRjI4aDdzd0VaVzM1QUZTWU5EdmJWOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:39:52+00:00", "published_display": "22 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTFB4RnptWjVmeU1keDREX1ZzOWJJMEFyaFl6VDItWUZZcGZUcWRqbXdmMXBrbE5HQzcwVW5hZlhmaTc4UDF5a3BZcDdkTS0xZnA3aUY1X0pxa0g3SjJZcGZvVk02UWwydW40RUpMOU00ZVVLRkZCWkc2a0RR?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:38:45+00:00", "published_display": "22 Jun 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFB4QkhaSk1US1FBT3ljX0NhODI1TlFlcU9CeU1mRnFQNlRwVXo1ZHIzRmZzWGlQZ1JaUFMtYzJ4dG1vMGNESERQOWRraFR3OTNFZVduU2JDZktNNk5FSjA4NkZkMFdQWFpKWWdWeWVmWQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:38:41+00:00", "published_display": "22 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1HWm1qOTZsVEFVSmQ2RWxaS0ROX2dac1hJZ1ZzMk1hWU94TnBzYjZETEJGdmdzd01SWkx4M2FaTzUxdVItamZ5Y3FtZnVodDE1aWtydjczSG1aLUVya08yVUhaX0kxdFV2eTRWVng1ZDVSS1FsV2lV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:08:53+00:00", "published_display": "22 Jun 2026 01:08", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-19T17:14:36+00:00", "published_display": "19 Jun 2026 17:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBKYkpKZUdZS0E2WXJzUTM1aDBpSjVmVHZkU0xmcDBZRHhTQWQ2SEdZY3NSbUpOZzZQTUMxWG1ZNEFmR3RsaW1sdlNiZ3hJRkctT2VWcXFrOWZuMTdQdEJtRWQ4WUNWbzh6VENzb1lPREVnSU91T1Z5VQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T09:37:53+00:00", "published_display": "17 Jun 2026 09:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9qUzhUcmJucFNYMVBLMHFaUmQ0WDNQd1VMenJoSXFpVElteUsyaXU3S0RBdnh6eXJPcGVmeU82a3poLXFmM3FiM3hsVUhhMzNvRktsU1dGUldzZktjUUh0TU1EUEdpc3ZMaUY1QU1GWXU?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T09:00:49+00:00", "published_display": "17 Jun 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBLNlNvMXVWa3hHSHRwR0hEOTNId2M0YUdXU0pDVV9aeGo3RWJBbE5TYWgyWmxDb3dNZ0VQdmRMOERBSmk0blEtbTBpMTMyWnBxYWRJWDY3alIwY0RadmN2SHhFS1o2WXU1SDNlRDNB?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T08:54:48+00:00", "published_display": "17 Jun 2026 08:54", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5hRHQteEJRRTMySTRrMDVsd2JuTUQ0emE5clhUTk5WLWNsckZyRXdZUGFOWUVMU1lYVDBMd1ZTQnlPdmlBMFllUkNsRVRNekhueFJMT1JHQmpfWVQzNl93dXd4SlRzcTZoZnU1cE9ZTkw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Turn Therapeutics Inc. \u2013 NASDAQ:TTRX", "summary": "The article provides information about Turn Therapeutics Inc. (NASDAQ: TTRX), focusing specifically on the number of shareholders. It indicates that further details on the shareholder count are available within the financial data section but doesn't list the exact numbers directl", "url": "https://www.tradingview.com/symbols/NASDAQ-TTRX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-15T12:09:44", "published_display": "15 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics posts positive GX-03 Phase 2 interim results, updates investor presentation", "summary": "Turn Therapeutics (TTRX) announced positive interim Phase 2 results for its topical drug GX-03, showing significant improvement in EASI scores for eczema and a favorable safety profile. The company also provided an updated investor presentation, detailing a development plan targe", "url": "https://www.tradingview.com/news/tradingview:4edb100a1fe7a:0-turn-therapeutics-posts-positive-gx-03-phase-2-interim-results-updates-investor-presentation/", "source_name": "TradingView", "published_at": "2026-06-03T10:09:29", "published_display": "03 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (NASDAQ: TTRX) details GX-03 interim data, onychomycosis plans and runway", "summary": "Turn Therapeutics provided an updated investor presentation detailing its dermatology pipeline, including the lead asset GX-03. The presentation highlighted positive interim Phase 2 data for GX-03 in moderate to severe atopic dermatitis, showing significant reductions in EASI sco", "url": "https://www.stocktitan.net/sec-filings/TTRX/8-k-turn-therapeutics-inc-reports-material-event-bad89df97afb.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:09:29", "published_display": "03 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis \u2013 Company Announcement - FT.com", "summary": "Turn Therapeutics announced positive interim analysis findings from its Phase 2 GX-03 trial for moderate-to-severe atopic dermatitis, with significant reductions in eczema severity observed. The company is using these findings to optimize the trial's second stage, including refin", "url": "https://markets.ft.com/data/announce/detail?dockey=600-202606010830BIZWIRE_USPRX____20260601_BW276401-1", "source_name": "Financial Times", "published_at": "2026-06-02T09:09:21", "published_display": "02 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch", "summary": "This article highlights several top biotech gainers from Monday's trading. Turn Therapeutics Inc. (TTRX) saw its stock rise over 20% after reporting positive interim analysis findings for its atopic dermatitis study, while Conexeu Sciences Inc. (CNXU) gained over 18% due to progr", "url": "https://www.rttnews.com/3657144/top-biotech-gainers-ttrx-turns-heads-lixt-shifts-to-ai-energy-cnxu-update-qtrx-trax-on-watch.aspx", "source_name": "RTTNews", "published_at": "2026-06-02T02:39:11", "published_display": "02 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results", "summary": "Turn Therapeutics Corporation announced positive interim results from its Phase 2a clinical trial for RevMya, a topical treatment for mild to moderate atopic dermatitis (eczema). The company reported significant improvements in eczema area and severity, alongside reductions in it", "url": "https://www.moomoo.com/news/post/70878849/turn-therapeutics-shares-higher-on-favorable-interim-eczema-drug-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-01T23:39:11", "published_display": "01 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics reports interim phase 2 data for eczema drug", "summary": "Turn Therapeutics Inc. announced positive interim Phase 2 results for its eczema drug, GX-03, showing significant reductions in eczema severity. The positive data has contributed to a nearly 49% stock increase over the past six months. The company plans to use these findings to o", "url": "https://m.uk.investing.com/news/stock-market-news/turn-therapeutics-reports-interim-phase-2-data-for-eczema-drug-93CH-4707100?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-01T19:09:29", "published_display": "01 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics interim Phase 2 analysis shows rapid, deep EASI responses and favorable safety for GX-03", "summary": "Turn Therapeutics reported positive interim results from its Phase 2 GX-03 trial for eczema. The analysis showed rapid and deep EASI responses, with 92.6% of patients achieving EASI-50 at four weeks, and favorable safety with no serious adverse events. The company plans to refine", "url": "https://www.tradingview.com/news/tradingview:fc665d5b2e7b0:0-turn-therapeutics-interim-phase-2-analysis-shows-rapid-deep-easi-responses-and-favorable-safety-for-gx-03/", "source_name": "TradingView", "published_at": "2026-06-01T13:09:20", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics publishes GX-03 dermatitis study results", "summary": "Turn Therapeutics Inc. published study results showing its experimental treatment GX-03 significantly reduced dermatitis severity in a mouse model. This research highlights GX-03's potential as a topical therapy targeting inflammatory pathways in moderate-to-severe atopic dermati", "url": "https://m.uk.investing.com/news/stock-market-news/turn-therapeutics-publishes-gx03-dermatitis-study-results-93CH-4700386?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-27T19:08:53", "published_display": "27 May 2026 19:08", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics publishes GX-03 dermatitis study results By Investing.com", "summary": "Turn Therapeutics (NASDAQ:TTRX) announced the publication of research demonstrating that its experimental treatment, GX-03, significantly reduced dermatitis severity in a mouse model. The study, published in the Journal of Dermatological Treatment, showed a mean investigator glob", "url": "https://m.au.investing.com/news/stock-market-news/turn-therapeutics-publishes-gx03-dermatitis-study-results-93CH-4457901?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-05-27T12:39:17", "published_display": "27 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model", "summary": "Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment, detailing the efficacy of its lead program, GX-03, in an IL-36 associated inflammatory model. The study demonstrated a statistically significant reduction in disease severity in a ", "url": "https://www.businesswire.com/news/home/20260527251995/en/Turn-Therapeutics-Announces-Peer-Reviewed-Publication-in-Journal-of-Dermatological-Treatment-Highlighting-GX-03-Activity-in-IL-36-Associated-Inflammatory-Model", "source_name": "Business Wire", "published_at": "2026-05-27T11:39:17", "published_display": "27 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026", "summary": "Turn Therapeutics Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026, where CEO Bradley Burnam will discuss the company's clinical-stage biotechnology and its lead investigational therapy, GX-03. GX-03 is a topical inhibitor for moderate-to-severe ato", "url": "https://www.pharmiweb.com/press-release/2026-05-19/turn-therapeutics-to-present-at-jefferies-global-healthcare-conference-2026", "source_name": "PharmiWeb.com", "published_at": "2026-05-19T14:39:37", "published_display": "19 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics CEO to Present at Jefferies Conference", "summary": "Turn Therapeutics Inc. (TTRX) CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be webcast live and available for replay, offering broad access to investors. TipRanks' AI Analyst, Spark, rates TTRX as Neutral due ", "url": "https://www.tipranks.com/news/company-announcements/turn-therapeutics-ceo-to-present-at-jefferies-conference", "source_name": "TipRanks", "published_at": "2026-05-19T13:10:56", "published_display": "19 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4", "summary": "Turn Therapeutics announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. He will provide an update on the company's clinical-stage biotech work, including its topical inhibitor GX-03 for atopic dermatitis, which is currently ", "url": "https://www.tradingview.com/news/tradingview:39ab19e580d6a:0-turn-therapeutics-to-present-at-jefferies-global-healthcare-conference-june-4/", "source_name": "TradingView", "published_at": "2026-05-19T12:10:56", "published_display": "19 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1", "summary": "Turn Therapeutics has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as its Executive Clinical and Regulatory Lead to guide the clinical and regulatory strategy for its lead investigational therapy, GX-03, for atopic dermatitis. Dr. Hahn brings extensive experience from ", "url": "https://www.minichart.com.sg/2026/05/18/turn-therapeutics-appoints-former-fda-commissioner-dr-stephen-hahn-to-lead-clinical-and-regulatory-strategy-for-gx-03-atopic-dermatitis-therapy-1/", "source_name": "Minichart", "published_at": "2026-05-18T16:09:18", "published_display": "18 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Appoints Former FDA Chief to Lead GX-03", "summary": "Turn Therapeutics, a clinical-stage biotechnology company, has appointed former FDA Commissioner Stephen M. Hahn, M.D., to lead the clinical and regulatory strategy for its investigational therapy, GX-03. GX-03, a topical inhibitor for moderate-to-severe atopic dermatitis, is cur", "url": "https://www.tipranks.com/news/company-announcements/turn-therapeutics-appoints-former-fda-chief-to-lead-gx-03?utm_source=edition.cnn.com&utm_medium=referral", "source_name": "TipRanks", "published_at": "2026-05-18T15:09:18", "published_display": "18 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development", "summary": "Turn Therapeutics has appointed former FDA Commissioner Dr. Stephen M. Hahn to lead the clinical and regulatory strategy for GX-03, its investigational therapy for moderate-to-severe atopic dermatitis. This move aims to strengthen the company's position in the competitive immunol", "url": "https://www.citybiz.co/article/847510/turn-therapeutics-recruits-former-fda-commissioner-stephen-hahn-to-guide-eczema-drug-development/", "source_name": "citybiz", "published_at": "2026-05-18T14:09:18", "published_display": "18 May 2026 14:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics appoints former FDA chief Stephen Hahn", "summary": "Turn Therapeutics Inc. has appointed Stephen M. Hahn, former FDA Commissioner, to head the clinical and regulatory strategy for its investigational topical therapy GX-03, currently in a Phase 2 trial for atopic dermatitis. The company, with a $121 million market cap, anticipates ", "url": "https://www.investing.com/news/company-news/turn-therapeutics-appoints-former-fda-chief-stephen-hahn-93CH-4695661", "source_name": "Investing.com", "published_at": "2026-05-18T13:09:18", "published_display": "18 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com", "summary": "Turn Therapeutics has appointed Stephen M. Hahn, former FDA Commissioner, to head its clinical and regulatory strategy for its investigational topical therapy GX-03. The therapy is in Phase 2 trials for atopic dermatitis, with results expected mid-2026. The company recently secur", "url": "https://ca.investing.com/news/stock-market-news/turn-therapeutics-appoints-former-fda-chief-stephen-hahn-93CH-4645472", "source_name": "Investing.com Canada", "published_at": "2026-05-18T12:09:52", "published_display": "18 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead", "summary": "Turn Therapeutics Inc. has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as its Executive Clinical and Regulatory Lead. Dr. Hahn will oversee the clinical and regulatory strategy for GX-03, the company's investigational topical therapy for moderate-to-severe atopic derm", "url": "https://www.businesswire.com/news/home/20260518335330/en/Turn-Therapeutics-Appoints-Physician-Scientist-and-Former-FDA-Commissioner-Dr.-Stephen-M.-Hahn-as-Executive-Clinical-and-Regulatory-Lead", "source_name": "Business Wire", "published_at": "2026-05-18T12:09:18", "published_display": "18 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "Turn Therapeutics reported its First Quarter 2026 financial results, highlighting a strengthened financial position due to a $7 million initial funding tranche from Avenue Capital Group. The company is advancing its Phase 2 clinical trial for GX-03 in moderate-to-severe atopic de", "url": "https://www.businesswire.com/news/home/20260511828716/en/Turn-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Updates", "source_name": "Business Wire", "published_at": "2026-05-11T20:10:18", "published_display": "11 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) Short Interest & Short Float | Updated Jun 2026 $TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE1Ca1JPaXQ5d2ppMDBYTmZGYy1qR2tjZ0JoSVBPdDNzVFltVXFVTHB6V3B4QkJ3OGlReGRnZm9CZ1F1NHJWM1V2cUdRSnlyUG9qVkZSQnpRTDJza2RSU1Q1LTI4aldBdEVGamZPSlJB?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-11T17:17:57+00:00", "published_display": "11 May 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy?", "summary": "Turn Therapeutics (NASDAQ:TTRX) saw its stock price rise by 6% on Friday, trading at $3.55, although with light trading volume. Analysts have a \"Hold\" rating on the stock, with an average price target of $8.00, stemming from one \"Buy\" rating and one \"Sell\" rating. The company, a ", "url": "https://www.marketbeat.com/instant-alerts/turn-therapeutics-nasdaqttrx-trading-6-higher-should-you-buy-2026-04-25/", "source_name": "MarketBeat", "published_at": "2026-04-25T06:39:02", "published_display": "25 Apr 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX Price Today: Turn Therapeutics Inc. Stock Price, Quote & Chart | MEXC", "summary": "This article provides current and historical stock performance data for Turn Therapeutics Inc. (TTRX), a clinical-stage biotechnology and medical device development company. It details key market data, price changes, and investment insights, along with a guide on how to buy TTRX ", "url": "https://www.mexc.co/stocks/ttrx", "source_name": "MEXC", "published_at": "2026-04-24T15:10:39", "published_display": "24 Apr 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates", "summary": "Turn Therapeutics reported its full-year 2025 financial results and provided corporate updates. The announcement was made via a press release disseminated through Quantisnow, a real-time market data platform for retail investors. Quantisnow Plus members received an alert shortly ", "url": "https://www.quantisnow.com/insight/turn-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates-6478950", "source_name": "Quantisnow", "published_at": "2026-04-11T08:40:43", "published_display": "11 Apr 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group", "summary": "Turn Therapeutics, a clinical-stage dermatology company, has secured up to $25 million in growth capital financing from Avenue Venture Opportunities Fund II, L.P. An initial $7 million has been funded, with the remaining $18 million contingent on achieving clinical and corporate ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/turn-therapeutics-secures-25-million-120000536.html", "source_name": "Market source", "published_at": "2026-04-10T20:39:43", "published_display": "10 Apr 2026 20:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M", "summary": "Turn Therapeutics Inc. CEO Burnam Bradley Evan, through his controlled entity BEB Holdings, LLC, reported a bona fide gift of 300,000 shares of common stock at a price of $0.00 per share. This transaction was identified as a non-cash, routine disposition, not a market sale, and l", "url": "https://www.stocktitan.net/sec-filings/TTRX/form-4-turn-therapeutics-inc-insider-trading-activity-415a093d6e2a.html", "source_name": "Stock Titan", "published_at": "2026-04-08T19:40:15", "published_display": "08 Apr 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE84TFhsR3VmcF8zdUhEVl8xRGRSc1FKbHhRaWl6OG5LbjJxay1lX0NVbzN1aTkyOHJWY0d2Y2pGQ0Y3LU44cElMNXNaWWRBNElTd2NhRHI4VW1sdmtQOG03ejQwcGFJUQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-10-30T20:17:28+00:00", "published_display": "30 Oct 2025 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) Stock Price, News & Analysis $TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9ZVzBUeGhUUU1NaTdKLVRuM0x4bGlHVVA4TzBDMDVFUG0yTFJFNVoxOUlxbG5hQVRPd25tUlhfd1B5MmdwMnBLRzZaV3dsVThwVHFhbjBxRC1HZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-10-30T09:18:58+00:00", "published_display": "30 Oct 2025 09:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX Stock Price and Chart \u2014 NASDAQ:TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9DYURreVlWc1JYWmZBZ19xVF9vY2Qxel92ZDJaY05UTGpvbHBuVy1sNkg0NmIxUnhoZk96dno1OHhwTG91SWpnLTBoaGxQWFluT2RiSjRLXzBFSzND?oc=5", "source_name": "TradingView", "published_at": "2025-10-12T07:00:00+00:00", "published_display": "12 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty\u2014PepsiCo", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxOdzA3OHpsMjhPVDZqSVBicjd3STVaQVNpVmlBTkItQVFDVlVsMjU5RjhQQWlaYk5KcExlTThpRjZLT2FFcDZpRW9EaXQwYUp6eXppem5WZGF1dTBxSnN6RE9SRENDWXkxOGV4UmZQUTRTVFlBQlFrb1RBX25rQ0tCQnVlSnlEczBfM29SNmpUZjNTdmFtMnVWSzZNMTZ4TGZ2Y1FsbFlDekxCajUwSW83OHNNRTVNU0xlVVg0Slc1UnJBRENoOWJqRGNmTGJxbDhpaGw5OVpwdDE0TEdiXzkyX0xvRld0aHgyVG40cGV4SXFuQjVmUFRaVFJDLUYtYlJLRXJzVURjTmNFNmRHbkx1ZkhmZUpRSzVlYkdKSENoMTNsZ2Y4dkE?oc=5", "source_name": "Benzinga", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSWxVcUJBQVJrd1BHTC03V2FsN1BNa1YyWFJkN0tfVVZxZlNGSldGR3YwQU15UVRwNmptZ1I3R1ZrLWpZOEN2amRTSHVuUm0zdGE4bFh3X1FXRWZ0eFNrT3A4bXJONTBFRHNQSnFpX3Y2aUJfNk14T0FzU2gzczNkNW1BelBCMlpoY1RVdnBnTjdRNzZhano3czdCcE81VEFuLVNSaGRNakQxa3FlU1dEWGx0Q2sxcmxlbGhLOFhGcWFoT0pPSlE?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE55aUZST196WV80Zjd1enQxcXFjbkVMMjE1RlFyaUZhdTN5TUJEWndLOTF4MU9BWndxX2VkbXJrTWFTUXd4X21nSHVsQlAyZlAw?oc=5", "source_name": "CNN", "published_at": "2025-10-08T14:10:26+00:00", "published_display": "08 Oct 2025 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX IPO News - Wound and dermatology-focused Turn Therapeutics set to direct list on the Nasdaq today, 10/8", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPYXpCM3dKNHkyVGM5cTA4aGhpMTRNM1dFUWFaaGdJcmt0Snd1ZUk3NjZBcFprRElkdFRWNjFRSWlIZ3Ytemk4Vm5oU2ZXRzRNRFhmZW5XeFJ4TFo4OFEyajNwWFF3T0NZSDRvMFBObDNSZy1tbmN0RHhOM2pmbHFJRVNtLTV5QVFLemp2Y3hoQXlqM2lEVnpEdUFMV01OekFIRFFkM0RRaUk5U0N0bWVEWTlQLVFZZlEyMWNTT2ttY3JtaTg2RC0xNDZSS1NoUQ?oc=5", "source_name": "renaissancecapital.com", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX IPO News - Wound and dermatology-focused Turn Therapeutics files for a direct listing on the Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxORXV2TkRtWk9td1RmYlRFdjNfb2cwQU5DTjVRLW1paGVnVUs4VkM2SU5mclp4YWtCLTBaRGpkN0daWUdBSDNNcnN1Q1R2eWFuQjFJb2hCT2UwNm5mc1oyV20yUnMzcGZrN2FYMjdNLXlmZ1RPQVByRjBWdzdHX1Nxb1BPbmExem45SmtNbGl2S0pfejljVndNckppWUpBZDRXU2x0Y290VkV6N2kyN0lCUGhPQ2o1NFpiUWZOZW9jZHBoYm9hMzQ3SFhPRW8wQQ?oc=5", "source_name": "renaissancecapital.com", "published_at": "2025-09-02T07:00:00+00:00", "published_display": "02 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Turn Therapeutics Ord Shs (TTRX) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5wVFNad2lYYXhSOEhDSm1KQkhaQ2p4VUh0T0JlVHZnejJqdmtVSzcyM2x2c1ZhSlhQa1ZITS1TajVGdVpGY0xVamRPbEREd1NmbkRIZGZoenBDYWFjOEJvU2VSZUhjRXROazVEOV9QOGY?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:40:16+00:00", "published_display": "22 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Valuation: PE, PB & Fair Value Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9BUFEwR1BVSlJXbVQ2bFV0VkxEOFZxcTZCSDB6YzNpV1ZlOTBMRmQ1S3dEc082OEZua0dvc0pnczBJMFpUOW11ZmNfcmt4NzdnRzdDV2ZiMkt2OGQtOS1uZWdlNjNMRjI4aDdzd0VaVzM1QUZTWU5EdmJWOA?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:39:52+00:00", "published_display": "22 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTFB4RnptWjVmeU1keDREX1ZzOWJJMEFyaFl6VDItWUZZcGZUcWRqbXdmMXBrbE5HQzcwVW5hZlhmaTc4UDF5a3BZcDdkTS0xZnA3aUY1X0pxa0g3SjJZcGZvVk02UWwydW40RUpMOU00ZVVLRkZCWkc2a0RR?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:38:45+00:00", "published_display": "22 Jun 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMib0FVX3lxTFB4QkhaSk1US1FBT3ljX0NhODI1TlFlcU9CeU1mRnFQNlRwVXo1ZHIzRmZzWGlQZ1JaUFMtYzJ4dG1vMGNESERQOWRraFR3OTNFZVduU2JDZktNNk5FSjA4NkZkMFdQWFpKWWdWeWVmWQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:38:41+00:00", "published_display": "22 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1HWm1qOTZsVEFVSmQ2RWxaS0ROX2dac1hJZ1ZzMk1hWU94TnBzYjZETEJGdmdzd01SWkx4M2FaTzUxdVItamZ5Y3FtZnVodDE1aWtydjczSG1aLUVya08yVUhaX0kxdFV2eTRWVng1ZDVSS1FsV2lV?oc=5", "source_name": "TradingKey", "published_at": "2026-06-22T01:08:53+00:00", "published_display": "22 Jun 2026 01:08", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-19T17:14:36+00:00", "published_display": "19 Jun 2026 17:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBKYkpKZUdZS0E2WXJzUTM1aDBpSjVmVHZkU0xmcDBZRHhTQWQ2SEdZY3NSbUpOZzZQTUMxWG1ZNEFmR3RsaW1sdlNiZ3hJRkctT2VWcXFrOWZuMTdQdEJtRWQ4WUNWbzh6VENzb1lPREVnSU91T1Z5VQ?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T09:37:53+00:00", "published_display": "17 Jun 2026 09:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9qUzhUcmJucFNYMVBLMHFaUmQ0WDNQd1VMenJoSXFpVElteUsyaXU3S0RBdnh6eXJPcGVmeU82a3poLXFmM3FiM3hsVUhhMzNvRktsU1dGUldzZktjUUh0TU1EUEdpc3ZMaUY1QU1GWXU?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T09:00:49+00:00", "published_display": "17 Jun 2026 09:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTFBLNlNvMXVWa3hHSHRwR0hEOTNId2M0YUdXU0pDVV9aeGo3RWJBbE5TYWgyWmxDb3dNZ0VQdmRMOERBSmk0blEtbTBpMTMyWnBxYWRJWDY3alIwY0RadmN2SHhFS1o2WXU1SDNlRDNB?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T08:54:48+00:00", "published_display": "17 Jun 2026 08:54", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Ord Shs (TTRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5hRHQteEJRRTMySTRrMDVsd2JuTUQ0emE5clhUTk5WLWNsckZyRXdZUGFOWUVMU1lYVDBMd1ZTQnlPdmlBMFllUkNsRVRNekhueFJMT1JHQmpfWVQzNl93dXd4SlRzcTZoZnU1cE9ZTkw?oc=5", "source_name": "TradingKey", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Turn Therapeutics Inc. \u2013 NASDAQ:TTRX", "summary": "The article provides information about Turn Therapeutics Inc. (NASDAQ: TTRX), focusing specifically on the number of shareholders. It indicates that further details on the shareholder count are available within the financial data section but doesn't list the exact numbers directl", "url": "https://www.tradingview.com/symbols/NASDAQ-TTRX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-15T12:09:44", "published_display": "15 Jun 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics posts positive GX-03 Phase 2 interim results, updates investor presentation", "summary": "Turn Therapeutics (TTRX) announced positive interim Phase 2 results for its topical drug GX-03, showing significant improvement in EASI scores for eczema and a favorable safety profile. The company also provided an updated investor presentation, detailing a development plan targe", "url": "https://www.tradingview.com/news/tradingview:4edb100a1fe7a:0-turn-therapeutics-posts-positive-gx-03-phase-2-interim-results-updates-investor-presentation/", "source_name": "TradingView", "published_at": "2026-06-03T10:09:29", "published_display": "03 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (NASDAQ: TTRX) details GX-03 interim data, onychomycosis plans and runway", "summary": "Turn Therapeutics provided an updated investor presentation detailing its dermatology pipeline, including the lead asset GX-03. The presentation highlighted positive interim Phase 2 data for GX-03 in moderate to severe atopic dermatitis, showing significant reductions in EASI sco", "url": "https://www.stocktitan.net/sec-filings/TTRX/8-k-turn-therapeutics-inc-reports-material-event-bad89df97afb.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:09:29", "published_display": "03 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis \u2013 Company Announcement - FT.com", "summary": "Turn Therapeutics announced positive interim analysis findings from its Phase 2 GX-03 trial for moderate-to-severe atopic dermatitis, with significant reductions in eczema severity observed. The company is using these findings to optimize the trial's second stage, including refin", "url": "https://markets.ft.com/data/announce/detail?dockey=600-202606010830BIZWIRE_USPRX____20260601_BW276401-1", "source_name": "Financial Times", "published_at": "2026-06-02T09:09:21", "published_display": "02 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch", "summary": "This article highlights several top biotech gainers from Monday's trading. Turn Therapeutics Inc. (TTRX) saw its stock rise over 20% after reporting positive interim analysis findings for its atopic dermatitis study, while Conexeu Sciences Inc. (CNXU) gained over 18% due to progr", "url": "https://www.rttnews.com/3657144/top-biotech-gainers-ttrx-turns-heads-lixt-shifts-to-ai-energy-cnxu-update-qtrx-trax-on-watch.aspx", "source_name": "RTTNews", "published_at": "2026-06-02T02:39:11", "published_display": "02 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results", "summary": "Turn Therapeutics Corporation announced positive interim results from its Phase 2a clinical trial for RevMya, a topical treatment for mild to moderate atopic dermatitis (eczema). The company reported significant improvements in eczema area and severity, alongside reductions in it", "url": "https://www.moomoo.com/news/post/70878849/turn-therapeutics-shares-higher-on-favorable-interim-eczema-drug-results?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-01T23:39:11", "published_display": "01 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics reports interim phase 2 data for eczema drug", "summary": "Turn Therapeutics Inc. announced positive interim Phase 2 results for its eczema drug, GX-03, showing significant reductions in eczema severity. The positive data has contributed to a nearly 49% stock increase over the past six months. The company plans to use these findings to o", "url": "https://m.uk.investing.com/news/stock-market-news/turn-therapeutics-reports-interim-phase-2-data-for-eczema-drug-93CH-4707100?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-01T19:09:29", "published_display": "01 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics interim Phase 2 analysis shows rapid, deep EASI responses and favorable safety for GX-03", "summary": "Turn Therapeutics reported positive interim results from its Phase 2 GX-03 trial for eczema. The analysis showed rapid and deep EASI responses, with 92.6% of patients achieving EASI-50 at four weeks, and favorable safety with no serious adverse events. The company plans to refine", "url": "https://www.tradingview.com/news/tradingview:fc665d5b2e7b0:0-turn-therapeutics-interim-phase-2-analysis-shows-rapid-deep-easi-responses-and-favorable-safety-for-gx-03/", "source_name": "TradingView", "published_at": "2026-06-01T13:09:20", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics publishes GX-03 dermatitis study results", "summary": "Turn Therapeutics Inc. published study results showing its experimental treatment GX-03 significantly reduced dermatitis severity in a mouse model. This research highlights GX-03's potential as a topical therapy targeting inflammatory pathways in moderate-to-severe atopic dermati", "url": "https://m.uk.investing.com/news/stock-market-news/turn-therapeutics-publishes-gx03-dermatitis-study-results-93CH-4700386?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-27T19:08:53", "published_display": "27 May 2026 19:08", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics publishes GX-03 dermatitis study results By Investing.com", "summary": "Turn Therapeutics (NASDAQ:TTRX) announced the publication of research demonstrating that its experimental treatment, GX-03, significantly reduced dermatitis severity in a mouse model. The study, published in the Journal of Dermatological Treatment, showed a mean investigator glob", "url": "https://m.au.investing.com/news/stock-market-news/turn-therapeutics-publishes-gx03-dermatitis-study-results-93CH-4457901?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-05-27T12:39:17", "published_display": "27 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model", "summary": "Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment, detailing the efficacy of its lead program, GX-03, in an IL-36 associated inflammatory model. The study demonstrated a statistically significant reduction in disease severity in a ", "url": "https://www.businesswire.com/news/home/20260527251995/en/Turn-Therapeutics-Announces-Peer-Reviewed-Publication-in-Journal-of-Dermatological-Treatment-Highlighting-GX-03-Activity-in-IL-36-Associated-Inflammatory-Model", "source_name": "Business Wire", "published_at": "2026-05-27T11:39:17", "published_display": "27 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026", "summary": "Turn Therapeutics Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026, where CEO Bradley Burnam will discuss the company's clinical-stage biotechnology and its lead investigational therapy, GX-03. GX-03 is a topical inhibitor for moderate-to-severe ato", "url": "https://www.pharmiweb.com/press-release/2026-05-19/turn-therapeutics-to-present-at-jefferies-global-healthcare-conference-2026", "source_name": "PharmiWeb.com", "published_at": "2026-05-19T14:39:37", "published_display": "19 May 2026 14:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics CEO to Present at Jefferies Conference", "summary": "Turn Therapeutics Inc. (TTRX) CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will be webcast live and available for replay, offering broad access to investors. TipRanks' AI Analyst, Spark, rates TTRX as Neutral due ", "url": "https://www.tipranks.com/news/company-announcements/turn-therapeutics-ceo-to-present-at-jefferies-conference", "source_name": "TipRanks", "published_at": "2026-05-19T13:10:56", "published_display": "19 May 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4", "summary": "Turn Therapeutics announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026. He will provide an update on the company's clinical-stage biotech work, including its topical inhibitor GX-03 for atopic dermatitis, which is currently ", "url": "https://www.tradingview.com/news/tradingview:39ab19e580d6a:0-turn-therapeutics-to-present-at-jefferies-global-healthcare-conference-june-4/", "source_name": "TradingView", "published_at": "2026-05-19T12:10:56", "published_display": "19 May 2026 12:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1", "summary": "Turn Therapeutics has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as its Executive Clinical and Regulatory Lead to guide the clinical and regulatory strategy for its lead investigational therapy, GX-03, for atopic dermatitis. Dr. Hahn brings extensive experience from ", "url": "https://www.minichart.com.sg/2026/05/18/turn-therapeutics-appoints-former-fda-commissioner-dr-stephen-hahn-to-lead-clinical-and-regulatory-strategy-for-gx-03-atopic-dermatitis-therapy-1/", "source_name": "Minichart", "published_at": "2026-05-18T16:09:18", "published_display": "18 May 2026 16:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Appoints Former FDA Chief to Lead GX-03", "summary": "Turn Therapeutics, a clinical-stage biotechnology company, has appointed former FDA Commissioner Stephen M. Hahn, M.D., to lead the clinical and regulatory strategy for its investigational therapy, GX-03. GX-03, a topical inhibitor for moderate-to-severe atopic dermatitis, is cur", "url": "https://www.tipranks.com/news/company-announcements/turn-therapeutics-appoints-former-fda-chief-to-lead-gx-03?utm_source=edition.cnn.com&utm_medium=referral", "source_name": "TipRanks", "published_at": "2026-05-18T15:09:18", "published_display": "18 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development", "summary": "Turn Therapeutics has appointed former FDA Commissioner Dr. Stephen M. Hahn to lead the clinical and regulatory strategy for GX-03, its investigational therapy for moderate-to-severe atopic dermatitis. This move aims to strengthen the company's position in the competitive immunol", "url": "https://www.citybiz.co/article/847510/turn-therapeutics-recruits-former-fda-commissioner-stephen-hahn-to-guide-eczema-drug-development/", "source_name": "citybiz", "published_at": "2026-05-18T14:09:18", "published_display": "18 May 2026 14:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics appoints former FDA chief Stephen Hahn", "summary": "Turn Therapeutics Inc. has appointed Stephen M. Hahn, former FDA Commissioner, to head the clinical and regulatory strategy for its investigational topical therapy GX-03, currently in a Phase 2 trial for atopic dermatitis. The company, with a $121 million market cap, anticipates ", "url": "https://www.investing.com/news/company-news/turn-therapeutics-appoints-former-fda-chief-stephen-hahn-93CH-4695661", "source_name": "Investing.com", "published_at": "2026-05-18T13:09:18", "published_display": "18 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com", "summary": "Turn Therapeutics has appointed Stephen M. Hahn, former FDA Commissioner, to head its clinical and regulatory strategy for its investigational topical therapy GX-03. The therapy is in Phase 2 trials for atopic dermatitis, with results expected mid-2026. The company recently secur", "url": "https://ca.investing.com/news/stock-market-news/turn-therapeutics-appoints-former-fda-chief-stephen-hahn-93CH-4645472", "source_name": "Investing.com Canada", "published_at": "2026-05-18T12:09:52", "published_display": "18 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 85, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead", "summary": "Turn Therapeutics Inc. has appointed Dr. Stephen M. Hahn, former FDA Commissioner, as its Executive Clinical and Regulatory Lead. Dr. Hahn will oversee the clinical and regulatory strategy for GX-03, the company's investigational topical therapy for moderate-to-severe atopic derm", "url": "https://www.businesswire.com/news/home/20260518335330/en/Turn-Therapeutics-Appoints-Physician-Scientist-and-Former-FDA-Commissioner-Dr.-Stephen-M.-Hahn-as-Executive-Clinical-and-Regulatory-Lead", "source_name": "Business Wire", "published_at": "2026-05-18T12:09:18", "published_display": "18 May 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "Turn Therapeutics reported its First Quarter 2026 financial results, highlighting a strengthened financial position due to a $7 million initial funding tranche from Avenue Capital Group. The company is advancing its Phase 2 clinical trial for GX-03 in moderate-to-severe atopic de", "url": "https://www.businesswire.com/news/home/20260511828716/en/Turn-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Updates", "source_name": "Business Wire", "published_at": "2026-05-11T20:10:18", "published_display": "11 May 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) Short Interest & Short Float | Updated Jun 2026 $TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE1Ca1JPaXQ5d2ppMDBYTmZGYy1qR2tjZ0JoSVBPdDNzVFltVXFVTHB6V3B4QkJ3OGlReGRnZm9CZ1F1NHJWM1V2cUdRSnlyUG9qVkZSQnpRTDJza2RSU1Q1LTI4aldBdEVGamZPSlJB?oc=5", "source_name": "MarketBeat", "published_at": "2026-05-11T17:17:57+00:00", "published_display": "11 May 2026 17:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy?", "summary": "Turn Therapeutics (NASDAQ:TTRX) saw its stock price rise by 6% on Friday, trading at $3.55, although with light trading volume. Analysts have a \"Hold\" rating on the stock, with an average price target of $8.00, stemming from one \"Buy\" rating and one \"Sell\" rating. The company, a ", "url": "https://www.marketbeat.com/instant-alerts/turn-therapeutics-nasdaqttrx-trading-6-higher-should-you-buy-2026-04-25/", "source_name": "MarketBeat", "published_at": "2026-04-25T06:39:02", "published_display": "25 Apr 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX Price Today: Turn Therapeutics Inc. Stock Price, Quote & Chart | MEXC", "summary": "This article provides current and historical stock performance data for Turn Therapeutics Inc. (TTRX), a clinical-stage biotechnology and medical device development company. It details key market data, price changes, and investment insights, along with a guide on how to buy TTRX ", "url": "https://www.mexc.co/stocks/ttrx", "source_name": "MEXC", "published_at": "2026-04-24T15:10:39", "published_display": "24 Apr 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates", "summary": "Turn Therapeutics reported its full-year 2025 financial results and provided corporate updates. The announcement was made via a press release disseminated through Quantisnow, a real-time market data platform for retail investors. Quantisnow Plus members received an alert shortly ", "url": "https://www.quantisnow.com/insight/turn-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates-6478950", "source_name": "Quantisnow", "published_at": "2026-04-11T08:40:43", "published_display": "11 Apr 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group", "summary": "Turn Therapeutics, a clinical-stage dermatology company, has secured up to $25 million in growth capital financing from Avenue Venture Opportunities Fund II, L.P. An initial $7 million has been funded, with the remaining $18 million contingent on achieving clinical and corporate ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/turn-therapeutics-secures-25-million-120000536.html", "source_name": "Market source", "published_at": "2026-04-10T20:39:43", "published_display": "10 Apr 2026 20:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M", "summary": "Turn Therapeutics Inc. CEO Burnam Bradley Evan, through his controlled entity BEB Holdings, LLC, reported a bona fide gift of 300,000 shares of common stock at a price of $0.00 per share. This transaction was identified as a non-cash, routine disposition, not a market sale, and l", "url": "https://www.stocktitan.net/sec-filings/TTRX/form-4-turn-therapeutics-inc-insider-trading-activity-415a093d6e2a.html", "source_name": "Stock Titan", "published_at": "2026-04-08T19:40:15", "published_display": "08 Apr 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) Stock Forecast and Price Target 2026 $TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE84TFhsR3VmcF8zdUhEVl8xRGRSc1FKbHhRaWl6OG5LbjJxay1lX0NVbzN1aTkyOHJWY0d2Y2pGQ0Y3LU44cElMNXNaWWRBNElTd2NhRHI4VW1sdmtQOG03ejQwcGFJUQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-10-30T20:17:28+00:00", "published_display": "30 Oct 2025 20:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Turn Therapeutics (TTRX) Stock Price, News & Analysis $TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9ZVzBUeGhUUU1NaTdKLVRuM0x4bGlHVVA4TzBDMDVFUG0yTFJFNVoxOUlxbG5hQVRPd25tUlhfd1B5MmdwMnBLRzZaV3dsVThwVHFhbjBxRC1HZw?oc=5", "source_name": "MarketBeat", "published_at": "2025-10-30T09:18:58+00:00", "published_display": "30 Oct 2025 09:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX Stock Price and Chart \u2014 NASDAQ:TTRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9DYURreVlWc1JYWmZBZ19xVF9vY2Qxel92ZDJaY05UTGpvbHBuVy1sNkg0NmIxUnhoZk96dno1OHhwTG91SWpnLTBoaGxQWFluT2RiSjRLXzBFSzND?oc=5", "source_name": "TradingView", "published_at": "2025-10-12T07:00:00+00:00", "published_display": "12 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty\u2014PepsiCo", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxOdzA3OHpsMjhPVDZqSVBicjd3STVaQVNpVmlBTkItQVFDVlVsMjU5RjhQQWlaYk5KcExlTThpRjZLT2FFcDZpRW9EaXQwYUp6eXppem5WZGF1dTBxSnN6RE9SRENDWXkxOGV4UmZQUTRTVFlBQlFrb1RBX25rQ0tCQnVlSnlEczBfM29SNmpUZjNTdmFtMnVWSzZNMTZ4TGZ2Y1FsbFlDekxCajUwSW83OHNNRTVNU0xlVVg0Slc1UnJBRENoOWJqRGNmTGJxbDhpaGw5OVpwdDE0TEdiXzkyX0xvRld0aHgyVG40cGV4SXFuQjVmUFRaVFJDLUYtYlJLRXJzVURjTmNFNmRHbkx1ZkhmZUpRSzVlYkdKSENoMTNsZ2Y4dkE?oc=5", "source_name": "Benzinga", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSWxVcUJBQVJrd1BHTC03V2FsN1BNa1YyWFJkN0tfVVZxZlNGSldGR3YwQU15UVRwNmptZ1I3R1ZrLWpZOEN2amRTSHVuUm0zdGE4bFh3X1FXRWZ0eFNrT3A4bXJONTBFRHNQSnFpX3Y2aUJfNk14T0FzU2gzczNkNW1BelBCMlpoY1RVdnBnTjdRNzZhano3czdCcE81VEFuLVNSaGRNakQxa3FlU1dEWGx0Q2sxcmxlbGhLOFhGcWFoT0pPSlE?oc=5", "source_name": "Stocktwits", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "symbol__ Stock Quote Price and Forecast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE55aUZST196WV80Zjd1enQxcXFjbkVMMjE1RlFyaUZhdTN5TUJEWndLOTF4MU9BWndxX2VkbXJrTWFTUXd4X21nSHVsQlAyZlAw?oc=5", "source_name": "CNN", "published_at": "2025-10-08T14:10:26+00:00", "published_display": "08 Oct 2025 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX IPO News - Wound and dermatology-focused Turn Therapeutics set to direct list on the Nasdaq today, 10/8", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPYXpCM3dKNHkyVGM5cTA4aGhpMTRNM1dFUWFaaGdJcmt0Snd1ZUk3NjZBcFprRElkdFRWNjFRSWlIZ3Ytemk4Vm5oU2ZXRzRNRFhmZW5XeFJ4TFo4OFEyajNwWFF3T0NZSDRvMFBObDNSZy1tbmN0RHhOM2pmbHFJRVNtLTV5QVFLemp2Y3hoQXlqM2lEVnpEdUFMV01OekFIRFFkM0RRaUk5U0N0bWVEWTlQLVFZZlEyMWNTT2ttY3JtaTg2RC0xNDZSS1NoUQ?oc=5", "source_name": "renaissancecapital.com", "published_at": "2025-10-08T07:00:00+00:00", "published_display": "08 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TTRX IPO News - Wound and dermatology-focused Turn Therapeutics files for a direct listing on the Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxORXV2TkRtWk9td1RmYlRFdjNfb2cwQU5DTjVRLW1paGVnVUs4VkM2SU5mclp4YWtCLTBaRGpkN0daWUdBSDNNcnN1Q1R2eWFuQjFJb2hCT2UwNm5mc1oyV20yUnMzcGZrN2FYMjdNLXlmZ1RPQVByRjBWdzdHX1Nxb1BPbmExem45SmtNbGl2S0pfejljVndNckppWUpBZDRXU2x0Y290VkV6N2kyN0lCUGhPQ2o1NFpiUWZOZW9jZHBoYm9hMzQ3SFhPRW8wQQ?oc=5", "source_name": "renaissancecapital.com", "published_at": "2025-09-02T07:00:00+00:00", "published_display": "02 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 61, "sentiment_summary": {"positive": 24, "negative": 2, "neutral": 35, "score": 60, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 10.94, "count": 21}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 24, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 5.87, "latest_week": "2026-06-19", "one_week_move": -2.9, "four_week_move": 14.4, "twelve_week_move": 69.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.892166, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 40.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 89.6296, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.9% over one week, +14.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 9}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "MarketBeat", "count": 4}, {"label": "Business Wire", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 21}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.9% over one week, +14.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Turn Therapeutics Ord Shs (TTRX) Institutional Confidence"}], "updated_at": "2026-06-22T20:44:37.822348+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}